… Stemmer, AstraZeneca; Ayala Hubert, AstraZeneca; Ora Rosengarten, AstraZeneca;
Mariana Steiner, AstraZeneca; Susan M. Domchek, AstraZeneca, AbbVie, Clovis Oncology …

Background Patients with advanced gastric or gastro-oesophageal junction cancer that
progresses on chemotherapy have poor outcomes. We compared pembrolizumab with paclitaxel …

Background Biliary tract cancers, which arise from the intrahepatic or extrahepatic bile ducts
and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide. …

Minimally invasive detection of cell death could prove an invaluable resource in many
physiologic and pathologic situations. Cell-free circulating DNA (cfDNA) released from dying cells …

Pancreatic ductal adenocarcinoma (PDA) represents an unmet therapeutic challenge. PDA
is addicted to the activity of the mutated KRAS oncogene which is considered so far an …

Objective The efficacy and safety of olaparib, an oral poly(ADP-ribose) polymerase (PARP)
inhibitor, was investigated in a subgroup of patients with germline BRCA1/2 mutated (…

Purpose The miniature biodegradable implant siG12D-LODER™ was inserted into a tumor
and released a siRNA drug against KRAS (G12D) along four months. This novel siRNA …

The oncofetal H19 gene transcribes a long non-coding RNA(lncRNA) that is essential for
tumor growth. Here we found that numerous established inducers of epithelial to mesenchymal …

Objectives To record the profile of toxic effects of polyethylene glycol–coated liposomal
doxorubicin hydrochloride (Doxil) to the skin, and to evaluate whether the long circulation pattern …

Background VEGF and VEGF receptor 2 (VEGFR-2)-mediated signalling and angiogenesis
can contribute to the pathogenesis and progression of gastric cancer. We aimed to assess …